ArticleScientific reports2026
Trends in renal failure-related mortality among U.S. multiple myeloma patients aged ≥ 45 years, 1999-2023: analysis of CDC data.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma (MM) is a plasma cell malignancy frequently complicated by renal impairment, which substantially worsens prognosis. Although therapeutic advances have improved MM survival, renal failure remains a major contributor to adverse outcomes. This study examined long-term trends and demographic disparities in mortality among U.S. decedents with MM listed as the underlying cause of death and renal failure listed as a contributing cause. Mortality data for adults aged ≥ 45 years from 1999 to 2023 were obtained from the CDC Wide-ranging Online Data for Epidemiologic Research (WONDER) database. Deaths were identified using ICD-10 codes, with MM (C90.0) as the underlying cause and renal failure (N17-N19) as a contributing cause. Age-adjusted mortality rates (AAMRs) and crude mortality rates (CMRs) were calculated by sex, race/ethnicity, region, age group, and urbanization level. Temporal trends were evaluated using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC). Overall mortality declined from 1999 to 2023, with the AAMR decreasing from 2.39 to 1.60 per 100,000 population (AAPC: -1.30). Despite this improvement, substantial disparities persisted. Males consistently exhibited higher AAMRs than females. Non-Hispanic Black individuals had the highest race-specific mortality rates. Residents of nonmetropolitan areas and those living in the Midwest experienced persistently higher mortality. Age-stratified analyses showed declining trends in most age groups, while adults aged ≥ 85 years demonstrated a modest recent increase. Mortality among U.S. adults with MM listed as the underlying cause of death and renal failure as a contributing cause declined between 1999 and 2023. However, persistent disparities by sex, race/ethnicity, region, urbanization, and age remain. These findings highlight the need for targeted strategies to reduce the burden of renal complications among high-risk MM populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.